Table 1.
Participant characteristics at first INSTI switch by CYP2B6 metabolizer genotype among participants with viral suppression at time of switch
| Characteristic | CYP2B6 metabolizer group | ||||
|---|---|---|---|---|---|
| Total (N = 138) |
Normal (N = 65) |
Intermediate (N = 56) |
Poor (N = 17) |
||
| Sexa | M | 115 (83%) | 58 (89%) | 45 (80%) | 12 (71%) |
| F | 23 (17%) | 7 (11%) | 11 (20%) | 5 (29%) | |
| Race/ethnicity | White non-Hispanic | 74 (54%) | 36 (55%) | 31 (55%) | 7 (41%) |
| Black non-Hispanic | 37 (27%) | 15 (23%) | 15 (27%) | 7 (41%) | |
| Hispanic | 25 (18%) | 12 (18%) | 10 (18%) | 3 (18%) | |
| Other | 2 (1%) | 2 (3%) | 0 (0%) | 0 (0%) | |
| First post-switch INSTI | RAL | 26 (19%) | 13 (20%) | 10 (18%) | 3 (18%) |
| EVG | 38 (28%) | 20 (31%) | 13 (23%) | 5 (29%) | |
| DTG | 67 (49%) | 30 (46%) | 29 (52%) | 8 (47%) | |
| BIC | 7 (5%) | 2 (3%) | 4 (7%) | 1 (6%) | |
| Age at first INSTI switch | Median (Q1, Q3) | 55 (48, 61) | 53 (47, 60) | 57 (49, 64) | 54 (52, 60) |
| TDF in regimen before switch | No | 49 (36%) | 24 (37%) | 20 (36%) | 5 (29%) |
| Yes | 89 (64%) | 41 (63%) | 36 (64%) | 12 (71%) | |
| Selected NRTIs in first post-switch regimen | ABC | 49 (36%) | 25 (38%) | 19 (34%) | 5 (29%) |
| TDF | 39 (28%) | 19 (29%) | 15 (27%) | 5 (29%) | |
| TAF | 40 (29%) | 16 (25%) | 19 (34%) | 5 (29%) | |
| OTHER | 10 (7%) | 5 (8%) | 3 (5%) | 2 (12%) | |
| Years prior D4T exposure | Median (Q1, Q3) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) |
| Years prior DDI exposure | Median (Q1, Q3) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) |
| Years prior ZDV exposure | Median (Q1, Q3) | 2.0 (0.0, 6.6) | 2.7 (0.0, 6.0) | 1.2 (0.0, 6.8) | 0.0 (0.0, 6.8) |
| Years prior D4T/DDI/ZDV exposure | Median (Q1, Q3) | 3.3 (0.0, 7.2) | 3.3 (0.0, 6.6) | 3.4 (0.0, 9.1) | 0.0 (0.0, 8.3) |
| Most recent CD4 count before switch | Median (Q1, Q3) | 709 (512, 916) | 717 (553, 933) | 640 (487, 818) | 878 (622, 1042) |
| Nadir CD4 before switch | Median (Q1, Q3) | 164 (39, 275) | 200 (55, 297) | 157 (38, 271) | 43 (20, 149) |
| Most recent BMI on or before switch | Median (Q1, Q3) | 26.9 (24.0, 30.0) | 27.1 (23.7, 29.3) | 26.5 (24.3, 29.8) | 28.1 (25.2, 31.4) |
| Weight at INSTI switch in kg | N | 81 | 36 | 33 | 12 |
| Median (Q1, Q3) | 82.2 (72.2, 94.0) | 81.8 (74.0, 93.6) | 79.0 (70.2, 91.8) | 88.8 (74.7, 104.5) | |
| History of diabetes at switch | 20 (14%) | 6 (9%) | 11 (20%) | 3 (18%) | |
| History of smoking at switch | 76 (55%) | 34 (52%) | 34 (61%) | 8 (47%) | |
| Week of first INSTI regimen from baseline | Median (Q1, Q3) | 687 (501, 837) | 651 (450, 817) | 716 (535, 858) | 687 (582, 807) |
| Duration of first INSTI regimen (weeks) | Median (Q1, Q3) | 143 (78, 203) | 152 (78, 209) | 134 (76, 194) | 141 (94, 163) |
| Study | A5001 | 22 (16%) | 13 (20%) | 6 (11%) | 3 (18%) |
| A5001+A5322 | 116 (84%) | 52 (80%) | 50 (89%) | 14 (82%) | |
| Psychiatric medication at switch | No | 135 (98%) | 64 (98%) | 55 (98%) | 16 (94%) |
| Yes | 3 (2%) | 1 (2%) | 1 (2%) | 1 (6%) | |
D4T, stavudine; DDI, didanosine; INSTI, integrase strand transfer inhibitor; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
a
Information regarding gender identity is not available from study participants.